Pricing Log in Create free account
Friday 6 November 2026 Export VTRS’s income statement to Excel — free account

Viatris Inc.

VTRS Healthcare Drug Manufacturers Specialty & Generic

Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024.

Revenue
−0.28%
EPS
−154.6%
Free cash flow
+38.8%
Total debt
−89.4%

Quarter to September 2026, against a year earlier

19.72 0.75 +3.95%
Market cap
$21.8B
P/E
0.0×
Fwd P/E
82.6×
Dividend yield
2.54%
F-score
4/9
Altman Z
0.61
Beneish M
−3.29
Dividend safety
37/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Viatris Inc. (VTRS) SEC filings, changes and red flags

Red flags

No red flags have been raised by Viatris Inc.’s filings on file.

Filings

Form Period Filed What it reports Flags
10-Q Sep 30, 2026 P1I2: 10 added · 6 removed · 51 modified
P2I1A: no comparison — the earlier filing's Item cannot be compared
8-K Nov 5, 2026 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Oct 8, 2026 1.01 Entry into a material definitive agreement; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026
8-K Aug 6, 2026 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Jul 1, 2026 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 9.01 Financial statements and exhibits
8-K Jun 17, 2026 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 9.01 Financial statements and exhibits
8-K Jun 12, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K May 15, 2026 5.07 Submission of matters to a vote of security holders
10-Q Mar 31, 2026 P1I2: 12 added · 63 removed · 56 modified
P2I1A: no material changes, the filing says
8-K May 7, 2026 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
8-K May 1, 2026 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-K Dec 31, 2025
8-K Feb 23, 2026 2.02 Results of operations and financial condition; 2.05 Costs of exit or disposal activities; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Jan 29, 2026 5.02 Departure or appointment of directors or officers
8-K Dec 8, 2025 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Dec 5, 2025 5.07 Submission of matters to a vote of security holders
8-K/A Aug 4, 2025 5.02 Departure or appointment of directors or officers
10-Q Sep 30, 2025 P1I2: 5 added · 1 removed · 50 modified
P2I1A: no comparison — the earlier filing's Item cannot be compared
8-K Nov 6, 2025 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Oct 24, 2025 5.03 Amendments to the articles or bylaws; change in fiscal year; 5.08 Shareholder director nominations; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025 P1I2: no comparison — no earlier filing on file
P2I1A: no comparison — incorporated by reference
10-K Dec 31, 2024 1: no comparison — no earlier filing on file
1A: no comparison — no earlier filing on file
7: no comparison — no earlier filing on file

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.